Its blueprint will require at least £12mln of funding – which would cover the cost of a glasshouse operation in Wiltshire – and probably more if it is to fully bankroll its ambitious blueprint.
Sativa is taking its cue from Canada, which first approved the drug for medical use 18 years ago, and is now home to vertically integrated cannabis giants such as Canopy Growth (now listed in New York and worth just shy of US$10bn).
Also revealed in the strategic update was the company’s desire to advance its venture with Lexamed of Germany to provide a distribution channel for its medicinal cannabis and cannabinol, or CBD products.
Wellness retail centres
Also under consideration, are CBD wellness retail centres and clinics and the group will assess the potential veterinary use of the ‘herb’.
Sativa said there had been a change of sentiment in the UK towards the industry from the regulators, government and the medical profession.
There is a growing belief among these groups that the drug may have a role to play in areas such as pain relief that avoids the use of addictive opioids.
“The company's operations now cover seed growing, in so far as the company has already successfully grown a hemp crop under the CEO's own growers' licence, and along with great strides in developing its medical cannabis business, and has researched, tested, marketed and sold CBD products,” explained Geremy Thomas, Sativa’s founder and chief executive.
"Sativa now has a solid base on which to build its seed-to-consumer model and this next round of fundraising will allow institutions and other investors to participate in what is expected to be a major UK industry."
Listed on the NEX exchange less than nine months ago, Sativa was set up to make investments into Canada-based or dual-listed cannabis companies.
It has so far ploughed cash into six early-stage businesses, including Veritas Pharma and George Botanicals.